Canada Cancer Clinicians’ Perceptions of Palliative Care in Pancreatic Cancer: A National Survey
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Survey Development and Software
2.3. Survey Participants and Distribution
2.4. Data Collection
2.5. Data Cleaning
2.6. Data Analysis
3. Results
3.1. Sample Characteristics
3.2. Survey Responses
3.2.1. Attitudes Toward Palliative Care
3.2.2. Barriers and Facilitators to Access and Referral
3.2.3. Free-Text Responses
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| GI | Gastrointestinal |
| GP | General practitioner |
Appendix A
Appendix A.1
| Section/Topic | Item | Item Description | Reported on Page # |
|---|---|---|---|
| Title and abstract | |||
| Title and abstract | 1a | State the word “survey” along with a commonly used term in title or abstract to introduce the study’s design. | p. 1 |
| 1b | Provide an informative summary in the abstract, covering background, objectives, methods, findings/results, interpretation/discussion, and conclusions. | pp. 1–2 | |
| Introduction | |||
| Background | 2 | Provide a background for the rationale of study, what has been previously done, and why this survey is needed. | p. 2 |
| Purpose/aim | 3 | Identify specific purposes, aims, goals, or objectives of the study. | p. 2 |
| Methods | |||
| Study design | 4 | Specify the study design in the methods section with a commonly used term (e.g., cross-sectional or longitudinal). | p. 3 |
| Data collection methods | 5a | Describe the questionnaire (e.g., number of sections, number of questions, number and names of instruments used). | p. 3 (followed description available from initial survey paper [19]) |
| 5b | Describe all questionnaire instruments that were used in the survey to measure particular concepts. Report target population, reported validity and reliability information, scoring/classification procedure, and reference links (if any). | Instruments not used in this manner; description of items given on p. 3 | |
| 5c | Provide information on pre-testing of the questionnaire, if performed (in the article or in an online supplement). Report the method of pre-testing, number of times questionnaire was pre-tested, number and demographics of participants used for pre-testing, and the level of similarity of demographics between pre-testing participants and sample population. | p. 3 | |
| 5d | Questionnaire, if possible, should be fully provided (in the article, or as appendices or as an online supplement). | Appendix A.2 | |
| Sample characteristics | 6a | Describe the study population (i.e., background, locations, eligibility criteria for participant inclusion in survey, exclusion criteria). | p. 3 |
| 6b | Describe the sampling techniques used (e.g., single stage or multistage sampling, simple random sampling, stratified sampling, cluster sampling, convenience sampling). Specify the locations of sample participants whenever clustered sampling was applied. | p. 3, described distribution narratively | |
| 6c | Provide information on sample size, along with details of sample size calculation. | Denominator information unavailable to inform sample size calculation; described in limitations (p. 9) | |
| 6d | Describe how representative the sample is of the study population (or target population if possible), particularly for population-based surveys. | Unknown; potential effect of response bias described in limitations (p. 9) | |
| Survey administration | 7a | Provide information on modes of questionnaire administration, including the type and number of contacts, the location where the survey was conducted (e.g., outpatient room or by use of online tools, such as SurveyMonkey). | High-level information given on p. 3 |
| 7b | Provide information on the survey’s time frame, such as periods of recruitment, exposure, and follow-up days. | p. 3 | |
| 7c | Provide information on the entry process:
| pp. 3–4 | |
| Study preparation | 8 | Describe any preparation process before conducting the survey (e.g., interviewers’ training process, advertising the survey). | N/A; p. 3 describes evolving survey distribution |
| Ethical considerations | 9a | Provide information on ethical approval for the survey if obtained, including informed consent, institutional review board [IRB] approval, Helsinki declaration, and good clinical practice [GCP] declaration (as appropriate). | p. 3 |
| 9b | Provide information about survey anonymity and confidentiality and describe what mechanisms were used to protect unauthorized access. | N/A; use of secure REDCap, distribution mechanism, and data cleaning processes on pp. 3–4 | |
| 10a | Describe statistical methods and analytical approach. Report the statistical software that was used for data analysis. | Analytical approach described on p. 4 | |
| 10b | Report any modification of variables used in the analysis, along with reference (if available). | p. 4 | |
| 10c | Report details about how missing data was handled. Include rate of missing items, pp. 4–5 missing data mechanism (i.e., missing completely at random [MCAR], missing at random [MAR] or missing not at random [MNAR] and methods used to deal with missing data (e.g., multiple imputation). | p. 4; missing data reported as such, not replaced. | |
| 10d | State how non-response error was addressed. | Described in limitations (p. 9) | |
| 10e | For longitudinal surveys, state how follow-up was addressed. | N/A | |
| 10f | Indicate whether any methods such as weighting of items or propensity scores have been used to adjust for non-representativeness of the sample. | N/A | |
| 10g | Describe any sensitivity analysis conducted. | N/A | |
| Results | |||
| 11a | Report numbers of individuals at each stage of the study. Consider using a flow diagram, if possible. | N/A; initial denominator/pool of potential participants unknown (lack of registry). | |
| 11b | Provide reasons for non-participation at each stage, if possible. | N/A; per above. | |
| 11c | Report response rate, present the definition of response rate or the formula used to calculate response rate. | N/A; denominator unknown. | |
| 11d | Provide information to define how unique visitors are determined. Report number of unique visitors along with relevant proportions (e.g., view proportion, participation proportion, completion proportion). | Unique respondents determined by email address during data cleaning (p. 4); unique views/visits not collected. | |
| 12 | Provide characteristics of study participants, as well as information on potential confounders and assessed outcomes. | pp. 4–5 and Table 1 | |
| 13a | Give unadjusted estimates and, if applicable, confounder-adjusted estimates along with 95% confidence intervals and p-values. | N/A | |
| 13b | For multivariable analysis, provide information on the model building process, model fit statistics, and model assumptions (as appropriate). | N/A | |
| 13c | Provide details about any sensitivity analysis performed. If there are a considerable amount of missing data, report sensitivity analyses comparing the results of complete cases with that of the imputed dataset (if possible). | N/A; data relatively complete. | |
| Discussion | |||
| 14 | Discuss the limitations of the study, considering sources of potential biases and imprecisions, such as non-representativeness of the sample, study design, important uncontrolled confounders. | p. 9 | |
| 15 | Give a cautious overall interpretation of results, based on potential biases and imprecisions and suggest areas for future research. | pp. 8–9 | |
| 16 | Discuss the eternal validity of the results. | p. 8 (discussed alignment with other research) | |
| Other sections | |||
| 17 | State whether any funding organization has had any roles in the survey’s design, implementation, and anlaysis. | Funder acknlowledged on p. 10; funders not involved in any of these activities | |
| 18 | Declare any potential conflict of interest. | p. 10 | |
| 19 | Provide names of organizations/persons that are acknowledged along with their contribution to the research. | p. 10 | |
Appendix A.2
| Section | Question | Response Options |
|---|---|---|
| Demographic Information | Gender |
|
| Race |
| |
| Age |
| |
| Province |
| |
| Urban/Rural |
| |
| Clinical Experience | What is your profession? |
|
| How many years of experience do you have in oncology? |
| |
| How many patients with pancreatic cancer do you see per year on average? |
| |
| Attitudes Towards Palliative Care | How important do you think palliative care is in the care of patients with pancreatic cancer? |
|
| How confident are you in providing palliative care to patients with pancreatic cancer? |
| |
| How satisfied are you with the quality of palliative care provided to patients with pancreatic cancer in your care setting? |
| |
| In your dealings with patients with pancreatic cancer, how often do you collaborate with… …a palliative care medical specialist? …a palliative care nurse specialist? …home-based palliative care? …an inpatient hospice? …a psychiatrist? …a psychologist? |
| |
| In your dealings with patients with pancreatic cancer, how often are you directly involved with… …managing cancer pain? …managing dyspnea? …managing fatigue? …managing nausea and vomiting? …managing the complications of chemotherapy? …managing the psychological consequences of advanced cancer (e.g., depression and anxiety)? …managing delirium? …managing constipation or diarrhea? …discussing end of life preferences with patients? …directly administering end of life care to dying cancer patients? …coordinating meetings with the family of dying patients? …recommending an inpatient hospice? |
| |
| Do you agree with the following statements about the management of patients with advanced cancer? …Medical oncologists should coordinate the care of pancreatic cancer patients at all stages of disease, including end of life care. …Palliative care begins where medical oncology ends. …I received good training in palliative care during my oncology fellowship (residency). …All advanced pancreatic cancer patients should receive concurrent palliative care even if they are receiving anti-tumor therapies. …The medical oncologist is the best person to coordinate the palliative care of patients with advanced pancreatic cancer. …A palliative care specialist is the best person to coordinate the palliative care of patients with advanced pancreatic cancer. …Medical oncologists should be expert in the management of the physical and psychological symptoms of advanced pancreatic cancer. …Most medical oncologists I know are expert in the management of the physical and psychological symptoms of advanced pancreatic cancer. …I am expert in the management of the physical and psychological symptoms of advanced pancreatic cancer. …Dying patients do not belong in the oncology ward. …All cancer centres should have a palliative care service. …I derive satisfaction from managing the physical symptoms of my patients. …Managing patients with advanced pancreatic cancer and dying patients depresses me. …I would rather have someone else look after my dying patients. …I am usually successful in managing my patient’s pain. …I derive satisfaction from my work managing patients with advanced pancreatic cancer and dying patients. …I feel emotionally burned out by having to deal with too many deaths. …I own a textbook of palliative care. …I read journals and papers related to the palliative care of advanced pancreatic cancer. …I am interested in participating in research in palliative treatments of advanced pancreatic cancer. …I deal with palliation in the nondying patients (“symptoms management”), but not with the palliation of the dying patient (“end of life care”). …I have a close working relationship with the palliative care (or hospice) services in my region. …Palliative care specialists “steal” patients who would otherwise benefit from medical oncology. …Palliative care (or hospice) physicians do not have enough understanding of oncology to counsel patients with advanced pancreatic cancer regarding their treatment options. |
| |
| Barriers to Access and Referral of Palliative Care | What do you perceive as the main barriers to accessing primary palliative care for patients with pancreatic cancer? (Select all that apply) |
|
| What do you perceive as the main barriers to referring patients with pancreatic cancer to specialty palliative care? (Select all that apply) |
| |
| What strategies have you used to overcome barriers to accessing and referring to palliative care? (Select all that apply) |
| |
| Open-Ended Comments | What other barriers or needs do you see in providing palliative care to patients with pancreatic cancer? | |
| Do you have any other comments? |
References
- Brenner, D.R.; Gillis, J.; Demers, A.A.; Ellison, L.F.; Billette, J.-M.; Zhang, S.X.; Liu, J.L.; Woods, R.R.; Finley, C.; Fitzgerald, N.; et al. Projected Estimates of Cancer in Canada in 2024. CMAJ 2024, 196, E615–E623. [Google Scholar] [CrossRef] [PubMed]
- Caban, M.; Małecka-Wojciesko, E. Gaps and Opportunities in the Diagnosis and Treatment of Pancreatic Cancer. Cancers 2023, 15, 5577. [Google Scholar] [CrossRef]
- Gyawali, B.; Booth, C.M. Treatment of Metastatic Pancreatic Cancer: 25 Years of Innovation with Little Progress for Patients. Lancet Oncol. 2024, 25, 167–170. [Google Scholar] [CrossRef]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef]
- Yang, J.; Xu, R.; Wang, C.; Qiu, J.; Ren, B.; You, L. Early Screening and Diagnosis Strategies of Pancreatic Cancer: A Comprehensive Review. Cancer Commun. 2021, 41, 1257–1274. [Google Scholar] [CrossRef]
- Scott, E.; Jewell, A. Supportive Care Needs of People with Pancreatic Cancer: A Literature Review. Cancer Nurs. Pract. 2019, 18. [Google Scholar] [CrossRef]
- Chung, V.; Sun, V.; Ruel, N.; Smith, T.J.; Ferrell, B.R. Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. J. Palliat. Med. 2022, 25, 720–727. [Google Scholar] [CrossRef]
- Lee, K.G.; Roy, V.; Laszlo, M.; Atkins, K.M.; Lin, K.J.; Tomassian, S.; Hendifar, A.E. Symptom Management in Pancreatic Cancer. Curr. Treat. Options Oncol. 2021, 22, 8. [Google Scholar] [CrossRef] [PubMed]
- Kim, C.A.; Lelond, S.; Daeninck, P.J.; Rabbani, R.; Lix, L.; McClement, S.; Chochinov, H.M.; Goldenberg, B.A. The Impact of Early Palliative Care on the Quality of Life of Patients with Advanced Pancreatic Cancer: The IMPERATIVE Case-Crossover Study. Support. Care Cancer 2023, 31, 250. [Google Scholar] [CrossRef]
- Bevins, J.; Bhulani, N.; Goksu, S.Y.; Sanford, N.N.; Gao, A.; Ahn, C.; Paulk, M.E.; Terauchi, S.; Pruitt, S.L.; Tavakkoli, A.; et al. Early Palliative Care Is Associated With Reduced Emergency Department Utilization in Pancreatic Cancer. Am. J. Clin. Oncol. 2021, 44, 181. [Google Scholar] [CrossRef] [PubMed]
- Radbruch, L.; De Lima, L.; Knaul, F.; Wenk, R.; Ali, Z.; Bhatnaghar, S.; Blanchard, C.; Bruera, E.; Buitrago, R.; Burla, C.; et al. Redefining Palliative Care—A New Consensus-Based Definition. J. Pain Symptom Manag. 2020, 60, 754–764. [Google Scholar] [CrossRef]
- Temel, J.S.; Greer, J.A.; El-Jawahri, A.; Pirl, W.F.; Park, E.R.; Jackson, V.A.; Back, A.L.; Kamdar, M.; Jacobsen, J.; Chittenden, E.H.; et al. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J. Clin. Oncol. 2017, 35, 834–841. [Google Scholar] [CrossRef]
- Balaban, E.P.; Mangu, P.B.; Khorana, A.A.; Shah, M.A.; Mukherjee, S.; Crane, C.H.; Javle, M.M.; Eads, J.R.; Allen, P.; Ko, A.H.; et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2016, 34, 2654–2668. [Google Scholar] [CrossRef] [PubMed]
- Sohal, D.P.S.; Kennedy, E.B.; Cinar, P.; Conroy, T.; Copur, M.S.; Crane, C.H.; Garrido-Laguna, I.; Lau, M.W.; Johnson, T.; Krishnamurthi, S.; et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J. Clin. Oncol. 2020, 38, 3217–3230. [Google Scholar] [CrossRef]
- Kruser, T.J.; Kruser, J.M.; Gross, J.P.; Moran, M.; Kaiser, K.; Szmuilowicz, E.; Kircher, S.M. Medical Oncologist Perspectives on Palliative Care Reveal Physician-Centered Barriers to Early Integration. Ann. Palliat. Med. 2020, 9, 2800–2808. [Google Scholar] [CrossRef]
- Smith, C.B.; Nelson, J.E.; Berman, A.R.; Powell, C.A.; Fleischman, J.; Salazar-Schicchi, J.; Wisnivesky, J.P. Lung Cancer Physicians’ Referral Practices for Palliative Care Consultation. Ann. Oncol. 2012, 23, 382–387. [Google Scholar] [CrossRef]
- Sharma, A.; Minh Duc, N.T.; Luu Lam Thang, T.; Nam, N.H.; Ng, S.J.; Abbas, K.S.; Huy, N.T.; Marušić, A.; Paul, C.L.; Kwok, J.; et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J. Gen. Intern. Med. 2021, 36, 3179–3187. [Google Scholar] [CrossRef]
- Cripe, J.C.; Mills, K.A.; Kuroki, L.K.; Wan, L.; Hagemann, A.R.; Fuh, K.C.; Mutch, D.G.; Powell, M.A.; Thaker, P.H. Gynecologic Oncologists’ Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. Gynecol. Obs. Investig. 2019, 84, 50–55. [Google Scholar] [CrossRef]
- Odejide, O.O.; Cronin, A.M.; Condron, N.B.; Fletcher, S.A.; Earle, C.C.; Tulsky, J.A.; Abel, G.A. Barriers to Quality End-of-Life Care for Patients With Blood Cancers. J. Clin. Oncol. 2016, 34, 3126–3132. [Google Scholar] [CrossRef] [PubMed]
- Meade, A.W.; Craig, S.B. Identifying Careless Responses in Survey Data. Psychol. Methods 2012, 17, 437–455. [Google Scholar] [CrossRef] [PubMed]
- Durall, A.; Zurakowski, D.; Wolfe, J. Barriers to Conducting Advance Care Discussions for Children with Life-Threatening Conditions. Pediatrics 2012, 129, e975–e982. [Google Scholar] [CrossRef]
- Kim, J.-Y.; Dalton, J.C.; Cort, N.; HerndonII, J.E.; Affronti, M.L.; Peters, K.B.; Jones, C.A.; Johnson, M.O. Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample. Am. J. Hosp. Palliat. Care 2024, 42, 10499091241280610. [Google Scholar] [CrossRef]
- Allard, E.; Dumaine, S.; Sasseville, M.; Gabet, M.; Duhoux, A. Quality of Palliative and End-of-Life Care: A Qualitative Study of Experts’ Recommendations to Improve Indicators in Quebec (Canada). BMC Palliat. Care 2024, 23, 146. [Google Scholar] [CrossRef] [PubMed]
- Dunn, S.; Earp, M.A.; Biondo, P.; Cheung, W.Y.; Kerba, M.; Tang, P.A.; Sinnarajah, A.; Watanabe, S.M.; Simon, J.E. Oncology Clinicians’ Challenges to Providing Palliative Cancer Care—A Theoretical Domains Framework, Pan-Cancer System Survey. Curr. Oncol. 2021, 28, 1483–1494. [Google Scholar] [CrossRef] [PubMed]
- Wentlandt, K.; Krzyzanowska, M.K.; Swami, N.; Rodin, G.M.; Le, L.W.; Zimmermann, C. Referral Practices of Oncologists to Specialized Palliative Care. J. Clin. Oncol. 2012, 30, 4380–4386. [Google Scholar] [CrossRef] [PubMed]
- Loprespub. Mapping Canada’s Urban and Rural Landscape; Library of Parliament HillNotes: Ottawa, ON, Canada, 2025. [Google Scholar]
| Characteristic | Response | Individuals (n, %) |
|---|---|---|
| Profession | RN (oncology nurse) | 84, 63% |
| General physician (GP oncologist, general medical oncologist) | 12 | |
| Specialist physician (GI specialist, radiation oncologist) | 38 | |
| Years of Practice | 0–5 years | 40, 30% |
| 6–10 years | 37 | |
| 11–15 years | 24 | |
| 16–20 years | 13 | |
| >20 years | 20 | |
| Patients with Pancreatic Cancer Seen Per Year on Average | 0 | 2 |
| 1 to 10 | 41 | |
| 11 to 25 | 50, 37% | |
| 26 to 50 | 29 | |
| >50 | 12 | |
| Gender | Female | 108, 81% |
| Male | 22 | |
| Prefer not to answer | 2 | |
| No data | 2 | |
| Race | White | 89, 66% |
| Asian (South Asian, East Asian, Southeast Asian) | 20 | |
| Black | 3 | |
| Indigenous (First Nations, Inuk/Inuit, Métis) | 2 | |
| Middle Eastern | 1 | |
| Other (Multiracial, Caribbean, Unspecified) | 4 | |
| Prefer not to answer | 6 | |
| No data | 9 | |
| Region/Province | Central (Ontario, Quebec) | 63, 47% |
| Western (Alberta, British Columbia, Manitoba, Saskatchewan) | 50 | |
| Atlantic (Newfoundland and Labrador, Nova Scotia, New Brunswick, Prince Edward Island) | 19 | |
| Urban/Rural | Urban | 108, 81% |
| Rural | 25 | |
| No data | 1 |
| How important do you think palliative care is in the care of patients with pancreatic cancer? | ||
| Very important | 131, 97.8% | |
| Important | 2, 1.5% | |
| Not important | 1, 0.7% | |
| How satisfied are you with the quality of palliative care provided to patients with pancreatic cancer in your care setting? | ||
| Very dissatisfied | 4, 3.0% | |
| Somewhat dissatisfied | 19, 14.2% | |
| Neutral | 22, 16.4% | |
| Somewhat satisfied | 62, 46.3% | |
| Very satisfied | 27, 20.1% | |
| Palliative care begins where medical oncology ends. 1 | ||
| Disagree | 121, 90.3% | |
| Don’t know | 2, 1.5% | |
| Agree | 11, 8.2% | |
| All advanced pancreatic cancer patients should receive concurrent palliative care even if they are receiving anti-tumor therapies. 1 | ||
| Disagree | 3, 2.2% | |
| Don’t know | 10, 7.5% | |
| Agree | 121, 90.3% | |
| What do you perceive as the main barriers to accessing primary palliative care for patients with pancreatic cancer? (Select all that apply) | |||
| n,% checked | |||
| Patient/family reluctance to accept palliative care | 97, 72.4% | ||
| Lack of knowledge about palliative care services | 68, 50.8% | ||
| Lack of support from other healthcare professionals | 54, 40.3% | ||
| Time constraints | 52, 38.8% | ||
| Lack of referral guidelines | 41, 30.6% | ||
| Other | 31, 23.1% | ||
| What do you perceive as the main barriers to referring patients with pancreatic cancer to specialty palliative care? (Select all that apply) | |||
| n,% checked | |||
| Lack of knowledge about palliative care services | 77, 57.5% | ||
| Patient/family reluctance to accept palliative care | 74, 55.2% | ||
| Lack of referral guidelines | 37, 27.6% | ||
| Lack of support from other healthcare professionals | 36, 26.9% | ||
| Time constraints | 34, 25.4% | ||
| Other | 16, 11.9% | ||
| What strategies have you used to overcome barriers to accessing and referring to palliative care? (Select all that apply) | |||
| n,% checked | |||
| Increased patient/family education about palliative care | 113, 84.3% | ||
| Increased collaboration with other healthcare professionals | 91, 67.9% | ||
| Attended palliative care education/training | 82, 61.2% | ||
| Used a referral decision aid/tool | 20, 14.9% | ||
| Other | 8, 6.0% | ||
| Resources within the healthcare system |
Examples:
|
| Collaboration amongst healthcare professionals |
Examples:
|
| Patient perceptions |
Examples:
|
| Exclusion criteria |
Examples:
|
| Guidelines |
Example:
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Valoo, K.; Durieux, B.N.; Subramaniam, K.; Du, T.; Perez, S.; Downar, J.; Fink, K.; Sanders, J.J. Canada Cancer Clinicians’ Perceptions of Palliative Care in Pancreatic Cancer: A National Survey. Curr. Oncol. 2026, 33, 113. https://doi.org/10.3390/curroncol33020113
Valoo K, Durieux BN, Subramaniam K, Du T, Perez S, Downar J, Fink K, Sanders JJ. Canada Cancer Clinicians’ Perceptions of Palliative Care in Pancreatic Cancer: A National Survey. Current Oncology. 2026; 33(2):113. https://doi.org/10.3390/curroncol33020113
Chicago/Turabian StyleValoo, Kamesha, Brigitte N. Durieux, Kajamathy Subramaniam, Ting Du, Samara Perez, James Downar, Karin Fink, and Justin J. Sanders. 2026. "Canada Cancer Clinicians’ Perceptions of Palliative Care in Pancreatic Cancer: A National Survey" Current Oncology 33, no. 2: 113. https://doi.org/10.3390/curroncol33020113
APA StyleValoo, K., Durieux, B. N., Subramaniam, K., Du, T., Perez, S., Downar, J., Fink, K., & Sanders, J. J. (2026). Canada Cancer Clinicians’ Perceptions of Palliative Care in Pancreatic Cancer: A National Survey. Current Oncology, 33(2), 113. https://doi.org/10.3390/curroncol33020113

